Use of a Four-miRNA Panel as a Biomarker for the Diagnosis of Stomach Adenocarcinoma
Table 1
Demographic and clinical manifestation of 246 participants (STAD and HCs).
Screening phase ()
Training phase ()
Validation phase ()
STAD (%)
HC (%)
STAD (%)
HC (%)
STAD (%)
HC (%)
Total number
20
12
30
24
80
80
Age at diagnosis
≤60
10 (50.0)
7 (58.3)
13 (43.3)
16 (66.7)
55 (68.8)
65 (81.2)
>60
10 (50.0)
5 (41.7)
17 (56.7)
8 (33.3)
25 (31.2)
15 (18.8)
Tumor diameter (mm)
≤50
15 (75.0)
17 (56.7)
65 (81.2)
>50
5 (25.0)
13 (43.3)
15 (18.8)
Lymphatic metastasis
Negative
8 (40.0)
11 (36.7)
20 (25.0)
Positive
12 (60.0)
19 (63.3)
60 (75.0)
TNM stage
I-II
7 (35.0)
16 (53.3)
35 (43.8)
III-IV
13 (65.0)
14 (46.7)
45 (56.2)
Differentiation
Poor
15 (75.0)
19 (63.3)
46 (57.5)
Moderate-well
5 (25.0)
11 (36.7)
34 (42.5)
Invasion depth
T1-T2
8 (40.0)
14 (46.7)
33 (41.3)
T3 - T4
12 (60.0)
16 (53.3)
47 (58.7)
In all three phases, there was no significant difference between STAD patients and HCs based on age. The parameter values are presented as a number (percentage). Statistical contrast was exerted using the Kruskal-Wallis rank test.
